1-3 of 3
Ivana N. Micallef
Close
Sort by
Journal Articles

Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy

Jessica F. Burlile, Kelsey M. Frechette, William G. Breen, Steven R. Hwang, Alexandra S. Higgins, Adrienne N. Nedved, William S. Harmsen, Sydney D. Pulsipher, Thomas E. Witzig, Ivana N. Micallef, Bradford S. Hoppe, Thomas M. Habermann, Gita Thanarajasingam, Patrick B. Johnston, David J. Inwards, N. Nora Bennani, Jennifer L. Peterson, Bradley J. Stish, William G. Rule, Stephen M. Ansell, Scott C. Lester
Journal: Blood Advances
Blood Adv (2024) 8 (5): 1250–1257.
https://doi.org/10.1182/bloodadvances.2023011533
Published: 2024
Includes: Supplemental data
Journal Articles

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome

Clinical Trials & Observations
Karan L. Chohan, Jason R. Young, Scott Lester, Muhamad Alhaj Moustafa, Allison Rosenthal, Han W. Tun, Bradford S. Hoppe, Patrick B. Johnston, Ivana N. Micallef, Thomas M. Habermann, Stephen M. Ansell
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4241–4250.
https://doi.org/10.1182/bloodadvances.2022007363
Published: 2022
Includes: Supplemental data
Journal Articles

Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era

Clinical Trials & Observations
Arushi Khurana, Mattia Novo, Grzegorz S. Nowakowski, Kay M. Ristow, Robert J. Spinner, Christopher H. Hunt, Rebecca L. King, Daniel H. Lachance, Thomas M. Habermann, Ivana N. Micallef, Patrick B. Johnston
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1379–1387.
https://doi.org/10.1182/bloodadvances.2020003666
Published: 2021
Includes: Supplemental data